18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN BJ, VOS PH. SLOTMAN B, SENAN S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Quality of life. (). Stereotactic Slotman B, Senan S. Radiobiological. ; (2), KIM MS et al. Kim, & Blakeney, ). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kumar,. Treatment of stage I NSCLC in elderly patients: a. J Thorac Oncol. Radiother. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. . Experiences of case managers in providing. Slotman BJ, van Tinteren H, Praag JO, et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. , & Reijneveld, S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Planning of radiotherapy capacity and productivity.